25928-05-6

Basic information

• Product Name: Dimethylcyclohexanone-2,6-dicarboxylate
• Synonyms: Dimethylcyclohexanone-2,6-dicarboxylate;2-Oxo-cyclohexane-1,3-dicarboxylicaciddimethylester
• CAS NO: 25928-05-6
• Molecular Formula: C₁₀H₁₄O₅
• Molecular Weight: 212.19928
• Mol File: 25928-05-6.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Dimethylcyclohexanone-2,6-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Dimethylcyclohexanone-2,6-dicarboxylate(25928-05-6)
• EPA Substance Registry System: Dimethylcyclohexanone-2,6-dicarboxylate(25928-05-6)

Safety Data

• Hazardous Substances Data: 25928-05-6(Hazardous Substances Data)

Upstream product

• 1830-54-2 3-oxopentanedioic acid dimethyl ester 
• 109-64-8 1,3-dibromo-propane 
• 124-38-9 carbon dioxide 
• 41302-34-5 2-(methoxycarbonyl)cyclohexanone 
• 74-88-4 methyl iodide 
• 186581-53-3 diazomethane 
• 108-94-1 cyclohexanone 
• 4861-79-4 magnesium methyl carbonate 

Downstream Products

• 876474-47-4 2-oxo-cyclohexane-1,3-dicarboxylic acid diamide 
• 1172691-07-4 7-([4-octyloxyphenyl]thien-2-yl)-2-(7-bromo{1,5-dimethyl spiro[bicyclo[3.3.1]nonane-9,9'-fluorene]}-2'-yl)spiro[bicyclo[3.3.1]nonane-9,9'-fluorene] 
• 1172691-06-3 C₄₇H₅₉BO₃S 
• 1172691-05-2 C₄₁H₄₇BrOS 
• 1172690-84-4 C₂₅H₂₇BrO₄ 
• 1172690-83-3 C₂₅H₂₈O₄ 
• 113161-21-0 dimethyl 3-benzyl-3-azabicyclo<3.3.1>nonan-9-one-1,5-dicarboxylate 
• 104035-85-0 dimethyl 2-hydroxy-1,3-cyclohexanedicarboxylate 

Relevant articles and documents

ELECTROLUMINESCENT MATERIALS COMPRISING FLUORENE DERIVATIVES

OLED compounds of the general structure: B—S-A-S—B in which rod-like nuclei A includes a condensed aromatic ring structure in turn having fluorene ring structures condensed with at least one additional fluorene ring structures wherein the fluorene ring systems provided by the condensed aromatic structure are substituted at the 9-position, and in which the 9-positions of the fluorenes are not susceptible to oxidation.

NOVEL COMPOUNDS AND METHODS OF USING THEM

The present invention relates to novel compounds and their pharmaceutically acceptable salts, prodrugs, solvates, polymorphs, tautomers and isomers. In some embodiments, the compounds described herein may be used to modulate sirtuins (SIRT). The present i